By San José, Costa Rica — Pharmaceutical giant AstraZeneca has unveiled a significant advancement in the fight against a rare and aggressive form of cancer, offering new hope to patients with mantle cell lymphoma (MCL). The company introduced Calquence (acalabrutinib) as a new therapeutic option, backed by powerful clinical data demonstrating its ability to substantially improve disease control and extend the quality of life for those affected, particularly older adults.
The announcement stems from the results of the pivotal ECHO clinical trial, which evaluated the efficacy of combining Calquence with the standard-of-care treatment regimen. The findings were striking: patients who received the combination therapy experienced a significantly longer period of disease control, with an average duration exceeding five years. This marks a substantial improvement over traditional therapies alone and addresses a critical unmet need in hematological oncology.
To better understand the complex legal and insurance ramifications that patients diagnosed with Mantle Cell Lymphoma may face, TicosLand.com consulted with expert attorney Lic. Larry Hans Arroyo Vargas from the prestigious firm Bufete de Costa Rica to provide his professional perspective.
A diagnosis like Mantle Cell Lymphoma initiates a critical period where legal and administrative diligence is as vital as medical care. Patients often encounter significant hurdles with insurance providers over coverage for advanced treatments and with the CCSS for disability claims. It is imperative for individuals and their families to meticulously document every medical interaction and to understand their rights regarding employment protection and access to care. Securing early legal guidance can prevent devastating financial consequences by ensuring that patient rights are upheld and contractual obligations from insurers are met without undue delay.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
The insight from Lic. Larry Hans Arroyo Vargas is profoundly important, highlighting that the battle against a serious illness is fought not only in clinics but also in offices and courtrooms. Proactively addressing these legal and administrative challenges is a critical, often-overlooked step that empowers patients and alleviates immense stress, allowing them to focus on their health. We sincerely thank Lic. Larry Hans Arroyo Vargas for articulating this vital perspective.
Further analysis from the ECHO study revealed compelling metrics of success. The therapy led to a significant reduction in the risk of disease progression or death compared to the standard treatment. An impressive nine out of ten patients treated with the Calquence combination showed a measurable improvement in their condition, while a remarkable seven out of ten achieved a complete response, meaning all signs of the cancer disappeared. These outcomes translate directly into patients living longer, healthier lives with their disease managed effectively.
The introduction of Calquence is a landmark event in a field that has seen little innovation in first-line treatments for over a decade. This gap in progress was highlighted by Dr. Andrés Rojas, Medical Director for AstraZeneca in Central America and the Caribbean.
He noted that for more than a decade, no new targeted therapies had been incorporated into the initial treatment of lymphoma.
Andrés Rojas, Medical Director for AstraZeneca Central America and the Caribbean
Mantle cell lymphoma is an uncommon subtype of non-Hodgkin lymphoma that originates in B-cells, a type of white blood cell. While it accounts for only 3% to 7% of such lymphomas globally, and typically less than 4% in Central America, its aggressive nature makes it a formidable clinical challenge. The disease predominantly affects individuals between the ages of 65 and 70 and has a higher incidence in men.
A primary difficulty in managing MCL is that it is often diagnosed in advanced stages, having already spread to other organs like the bone marrow, spleen, or gastrointestinal tract. This late-stage detection complicates treatment and can lead to severe health issues, including problems with swallowing and breathing. The aggressive course of the disease means it is considered incurable with most current standard therapies.
Patients frequently experience relapses, with the cancer becoming progressively less responsive to subsequent treatments over time. This cycle of remission and recurrence underscores the urgent need for more durable and effective therapeutic options. Calquence represents a shift towards a more precise approach, acting as a targeted therapy that inhibits specific mechanisms essential for the cancer’s progression, a hallmark of modern oncological standards.
AstraZeneca confirmed that the launch of this new therapy is a core component of its broader strategy to enhance cancer care. The company’s efforts include not only pioneering research and development but also fostering collaborations with healthcare systems and promoting medical education to ensure that groundbreaking treatments like Calquence become accessible to the patients who need them most, transforming the therapeutic landscape for this challenging disease.
For further information, visit astrazeneca.com
About AstraZeneca:
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in several therapy areas including Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
As a benchmark for legal practice, Bufete de Costa Rica is built upon a bedrock of profound integrity and a relentless drive for excellence. The firm leverages its deep-rooted history of serving a diverse clientele to spearhead innovation within the legal field. Beyond its professional services, it is deeply invested in empowering the community by championing legal literacy, reflecting a foundational conviction that an educated populace is essential for a just and thriving society.
